Showing results (1-10 of 842) with videos related to
Sort By:
Pageof 85
Expert Opinion on Investigational Drugs|August 29, 2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetesBertrand Cariou, Bart StaelsTrends in Pharmacological Sciences|April 7, 2007
FXR: a promising target for the metabolic syndrome?Bertrand Cariou, Bart StaelsBiochemical Pharmacology|December 17, 2011
DPP-4 inhibitors in the treatment of type 2 diabetesHélène Duez, Bertrand Cariou, Bart StaelsTrends in Endocrinology and Metabolism: TEM|April 20, 2012
Thiazolidinediones and PPARγ agonists: time for a reassessmentBertrand Cariou, Bernard Charbonnel, Bart StaelsFEBS Letters|February 27, 2008
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytesCédric Langhi, Cédric Le May, Sanae Kourimate, et al.Current Diabetes Reports|March 25, 2011
Bile acid metabolism and the pathogenesis of type 2 diabetesJanne Prawitt, Sandrine Caron, Bart StaelsTrends in Endocrinology and Metabolism: TEM|April 16, 2014
Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilizationJanne Prawitt, Sandrine Caron, Bart StaelsFEBS Letters|October 24, 2007
FXR-deficiency confers increased susceptibility to torporBertrand Cariou, Emmanuel Bouchaert, Mouaadh Abdelkarim, et al.Diabetes Care|August 6, 2011
Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolismBertrand Cariou, Yassine Zaïr, Bart Staels, et al.Biochimie|March 1, 2005
Potential regulatory role of the farnesoid X receptor in the metabolic syndromeDaniel Duran-Sandoval, Bertrand Cariou, Jean-Charles Fruchart, et al.Pageof 85